Heart, kidney, liver, joint, lung, mental health and skin findings for semaglutide and tirzepatide, with Fox noting which results are still preliminary.
Recap by typeshit. Full story at Fox News.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
European regulators flagged NAION, a sudden optic nerve injury, as a very rare possible side effect of semaglutide more than 15 months ago. Medscape looks at where that stands.
GoodRx explains how Wegovy fits into menopause weight management and what to ask a doctor about before considering it.
Loading…